Eicosanoid Inflammatory Mediators Are Robustly Associated with Blood Pressure in the General Population

Joonatan Palmu MD[1.2], Jeramie D. Watrous PhD[3], Kysha Mercader BSc[3],

Aki S. Havulinna DSc[2], Kim A. Lagerborg BSc[3], Aaro Salosensaari MSc[5],

Mike Inouye PhD[6,7], Martin G. Larson SD[7,8], Jian Rong PhD[7], Ramachandran S. Vasan[7],

Leo Lahti PhD[5], Allen Andres PhD[3], Susan Cheng MD[7,9,10], Pekka Jousilahti[2],

Veikko Salomaa MD[2], Mohit Jain MD[3]*, Teemu J. Niiranen MD[1,2,11]*

*Equal contribution

[1]Department of Internal Medicine, University of Turku, Finland

[2]Department of Public Health Solutions, Finnish Institute for Health and Welfare, Finland

[3]Departments of Medicine and Pharmacology, University of California, San Diego, CA

[4]Institute for Molecular Medicine Finland, FIMM-HiLIFE, Finland

[5]Department of Future Technologies, University of Turku, Finland

[6]Department of Public Health and Primary Care, University of Cambridge, United Kingdom

[7]National Heart, Lung and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA

[8]Department of Biostatistics, Boston University School of Public Health, Boston, MA

[9]Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA

[10]Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

[11]Division of Medicine, Turku University Hospital, Finland

Corresponding Author: Joonatan Palmu, Department of Internal Medicine, University of

Turku, Finland

e-mail: jjmpal@utu.fi; tel: +358 2 313 0000; fax: +358 2 313 8436

Total word count of manuscript: 5527

Abstract

Background Epidemiologic and animal studies have associated systemic inflammation with blood pressure (BP). However, the mechanistic factors linking inflammation and BP remain unknown. Fatty acid derived eicosanoids serve as mediators of inflammation and have been suggested to also regulate renal vascular tone, peripheral resistance, renin-angiotensin system, and endothelial function. We therefore hypothesize that specific pro- and anti-inflammatory eicosanoids modulate BP.

Methods In N=8099 FINRISK 2002 cohort participants randomly drawn from the Finnish population register (53% women, mean age 48±13 years), we profiled 545 distinct high-quality eicosanoids and related oxylipin mediators in plasma using non-targeted liquid chromatography-mass spectrometry. In models adjusted for conventional hypertension risk factors, we analyzed the associations of eicosanoids and eicosanoid profiles with systolic BP and hypertension. We used the Framingham Heart Study (FHS) Offspring study (N=2859) as the replication cohort.

Results We observed 187 eicosanoids (34%) significantly associated with systolic BP ($P <$ Bonferroni-corrected threshold of 0.05/545). 175 of these associations were positive and 12 were negative. Due to strong correlations between the eicosanoids, we used forward selection linear regression modeling to identify six eicosanoids independently related to systolic BP. A risk score based on these six eicosanoids was related to 40% (95% confidence interval [CI], 33–48%) and 32% (95% CI, 21–44%) greater odds of hypertension in FINRISK and FHS, respectively, per 1-SD score increase. Individuals in

the upper quartile of the six-eicosanoid risk score had 2.26-fold greater odds (95% CI, 1.96–2.62) of prevalent hypertension in FINRISK, compared with those in the lowest quartile. These findings were successfully replicated in an independent cohort of FHS participants.

Conclusions Plasma eicosanoids demonstrate strong associations with BP in the general population. Intriguingly, we observed specific protective molecules as well as harmful molecules. As eicosanoid compounds affect numerous physiological processes that are central to BP regulation, they may offer new insights regarding pathogenesis of hypertension, as well as serve as new targets for therapeutic intervention.

Keywords: blood pressure, eicosanoid, hypertension, liquid chromatography–mass spectrometry, metabolite

Introduction

A vast majority of hypertensive patients (>95%) are classified as having primary hypertension, a heterogeneous form of hypertension that by definition has no identifiable cause, but is most likely the consequence of an interaction between genetic factors and environmental factors (e.g., obesity, insulin resistance, sedentary lifestyle, stress, and sodium intake).[1] Intriguingly, all of the aforementioned factors are also related to chronic low-grade inflammation, underscoring the need to further investigate inflammation as a potential mainstay pathologic process underlying hypertension.[2]

The upstream initiation of inflammatory activity in humans is governed mainly by substrates and products of polyunsaturated fatty acids.[3] Termed eicosanoids, the small molecule derivatives of arachidonic acid and other polyunsaturated fatty acids serve as both activators and suppressors of systemic inflammatory activity.[3] Data derived mainly from animal studies suggest that eicosanoid compounds affect renal vascular tone, urine sodium excretion, peripheral resistance, kidney disease, renin-angiotensin-aldosterone system, and endothelial function – factors that are central to blood pressure (BP) regulation itself.[4–9] Published data have also demonstrated that a few, select eicosanoids, such as 20-hydroxyeicosatetraenoic acid (20-HETE), and genetic polymorphisms that regulate the levels of these eicosanoids, are altered in small samples of hypertensive individuals and animals.[10–12]

Until recently, sensitive methods for detecting and quantifying eicosanoids in large sample sizes were lacking. However, mass spectrometry (MS) based analytics now allow for the

rapid large-scale quantification several hundred upstream eicosanoids in human plasma.[13,14] Our goal was therefore to gain a more detailed understanding of how upstream inflammatory mediators are related to an individual's propensity for hypertension. We quantified a comprehensive panel of >500 distinct high-quality upstream eicosanoids and related oxylipin mediators in FINRISK 2002 (N=8099) and Framingham Heart Study Offspring (FHS Offspring; N=2859) cohort participants using liquid chromatography-MS (LC-MS) and related these eicosanoids and eicosanoid profiles with BP traits.

Methods

Cohorts

The FINRISK 2002 study is a random population sample of individuals aged 25–74 years from six geographical areas of Finland. The sampling was stratified by sex, region and 10-year age group for a population sample of 13500 individuals; the overall participation rate was 65.2% (N=8798). The sampling has been previously described in detail.[15] Plasma LC-MS was performed successfully on N=8292 participants. After excluding 193 participants with missing covariate data, N=8099 individuals were included in the analyses as the discovery cohort.

The first-generation (i.e. the 'Original') cohort of the FHS included a random sample of two thirds of the adult population of Framingham, MA who were enrolled in a longitudinal community-based cohort study in 1948. The FHS Offspring includes 5124 participants – children of the first-generation cohort and their spouses, who have been re-examined multiple times since the first examination in 1971. The characteristics and study protocol of FHS Offspring cohort have been published.[16] For this study, we considered N=3002 individuals with successful plasma LC-MS who participated in the eight examination cycle of FHS Offspring in 2005–2008. After excluding 143 participants for missing covariates, we included N=2859 participants as the replication cohort.

Ethical Approval

The FINRISK 2002 study was approved by Coordinating Ethics Committee of the Helsinki University Hospital District. FHS Offspring was approved by Boston University Medical

Center's institutional review board. All participants in both studies gave written informed consent. Participants' consent to publication of information was not required because the participants remain unidentifiable.

Clinical Evaluation and Definitions

Participants of both cohorts provided a medical history, including information on medication use, and underwent a physical examination and laboratory assessment of cardiovascular risk factors at baseline. The methodologies of these examinations have been described previously in detail.[15,16] At all examinations, a healthcare professional performed two (FHS Offspring) or three (FINRISK) sequential BP measurements using a mercury column sphygmomanometer on seated participants according to a standardized protocol. We defined the BP at a given examination as the mean of all sequentially measured BP values. We defined hypertension as BP ≥140/90 mmHg or use of antihypertensive medication. Antihypertensive medication use was based on self-report in both studies. We defined pulse pressure as systolic minus diastolic BP and mean arterial pressure as [(2 x diastolic BP) + systolic BP] / 3. We defined body mass index as weight (kg) divided by height (m) squared and current smoking as self-reported daily used of tobacco products. In FINRISK 2002, prevalent diabetes was defined as self-reported diabetes, a previous diagnostic code indicating diabetes in the nationwide Care Register for Health Care (International Statistical Classification of Diseases and Related Health Problems[17] (ICD) version 10 codes E10-E14, ICD-9 code 250, or ICD-8 code 250), a previous diabetes medication purchase (ATC code A10*) in the nationwide Prescribed Drug Purchase register, or a diabetes medication code in the nationwide Reimbursed

Medication Register. In FHS Offspring, prevalent diabetes was defined as a fasting plasma glucose ≥ 7.0 mmol/l or self-reported use of glucose-lowering medications.

Eicosanoid profiling

Using a directed non-targeted LC-MS approach in conjunction with computational chemical networking of spectral fragmentation patterns, we identified 545 eicosanoids and related oxylipins in the FINRISK. The methods of plasma eicosanoid profiling using LC-MS have been previously described in detail.[13,14] Metabolite data were adjusted for technical variation in off-plate pooled plasma samples and in spike-in internal standards. Missing values were replaced with minimum value for each eicosanoid abundance.

Statistical analyses

We normalized eicosanoid abundances using median absolute deviation; we calculated the median of the absolute difference from the median, and used this value to scale all analyte values for a given plate. We used linear and logistic regression models to examine the associations between each eicosanoid and BP traits (systolic BP, diastolic BP, pulse pressure, mean arterial pressure, and hypertension). We adjusted for multiple comparisons using Bonferroni correction to minimize the probability of type I error.[18] Relations between eicosanoids significantly associated with systolic blood arterial pressure were assessed using Spearman correlation and ordered using hierarchical cluster analysis with complete linkage method. We assessed the multivariable association between eicosanoids significantly related to systolic BP using stepwise linear regression modeling with forward selection and a Bonferroni-corrected inclusion threshold of p=0.05/545. For the six eicosanoids that remained in the models, we calculated eicosanoid risk scores

according to the formula $\beta_1X_1 + \beta_2X_2 + ... + \beta_nX_n$, with X_n denoting the standardized value

for the nth eicosanoid abundance, and β_n denoting the regression coefficient from the

regression model for systolic BP containing the indicated eicosanoids.[19] We assessed the

odds of hypertension and increase in systolic BP by 1-SD increases and by quartiles of the

risk scores using unadjusted and multivariable adjusted logistic and linear regression

models. We replicated these analyses in FHS Offspring using the eicosanoid abundances

in FHS and the regression coefficients from FINRISK. We adjusted all analyses for age,

sex, BMI, current smoking, diabetes, antihypertensive medication, and mass spectrometry

batch. We used R version 3.6.1[20] for all analyses. The source code for the analyses is

openly available at doi:10.5281/zenodo.3604123.[21]

Results

The characteristics of FINRISK (N=8099, mean age 48.0±13.1 years, 53.1% female) and FHS (N=2859, mean age 66.3±8.9 years, 54.7% female) cohorts are shown in **Table 1**.

Association between Eicosanoids and BP Traits

Of the eicosanoids, 187 (34.3%) were significantly associated with systolic BP, 124 (22.8%) with diastolic BP, 177 (32.5%) with mean arterial pressure, 161 (29.5%) with pulse pressure, and 155 (28.4%) with hypertension in FINRISK (**Figure 1, Table S1**). We selected systolic BP as our main outcome variable due to the greatest number of significant associations. We observed 175 (93.6%) positive and 12 (6.4%) negative associations for systolic BP (**Figure 1, Table S1**). The heatmaps of pairwise correlations for the 187 eicosanoids related to systolic BP are shown in **Figure 2** and **Figure S1**. This analysis revealed strong overall correlation, but only minor clustering of the eicosanoids.

Independent Eicosanoid Determinants of BP and Hypertension

Forward selection linear regression modeling with a Bonferroni-corrected inclusion threshold identified six eicosanoids positively associated with systolic BP in FINRISK, namely, 11-dehydro-2,3-dinor thromboxane B_2 (11-dehydro-2,3-dinor-TXB_2), 12-hydroxyheptadecatrienoic acid (11-HHTrE), 295.2279/4.89 (analyte; known eicosanoid analog), 5,6-epoxyeicosatrienic acid (5,6-EET), adrenic acid, and tetranor-12(R)-HETE (12-HETE) (**Figure 3)**. We observed four of these six eicosanoids in plasma samples in

the FHS Offspring cohort. These four eicosanoids were positively associated with systolic BP also in FHS Offspring (**Figure 3**).

Association of eicosanoid profiles with systolic BP and hypertension

We calculated an eicosanoid risk score based on the six previously mentioned eicosanoids that were independently associated with systolic BP in FINRISK. In an unadjusted model, individuals in the top quartile of the eicosanoid risk scores had 11.5 mmHg (95% confidence interval [CI] 10.3-12.7 mmHg) higher systolic BP, compared with individuals in the lowest quartile (**Figure 4**; **Table S2**). This BP difference was 9.0 mmHg (94% CI 8.0-10.1 mmHg) after adjusting for conventional hypertension risk factors. Each SD increment in the risk score was associated with an unadjusted and unadjusted increase of 4.5 (95% CI 4.0-4.9 mmHg) and 3.6 mmHg (95% CI 3.2-3.9 mmHg) in systolic BP, respectively (**Figure 4**; **Table S2**). Compared with participants in the bottom quartile of the risk score, individuals in the top quartile had 2.4- (95% CI 2.2-2.8) and 2.3-fold (95% CI 2.0-2.6) adjusted and unadjusted odds of hypertension, respectively (**Figure 5**; **Table S2**). Results were similar in FHS Offspring where the two non-detected eicosanoids were treated as zero valued measurements (**Figures 4 and 5**; **Table S2**).

Discussion

Using a directed non-targeted LC-MS approach in well-phenotyped, large population cohorts, we identified 187 eicosanoids and related oxylipins that were associated with systolic BP. FINRISK 2002 participants in the top quartile of a six-eicosanoid risk score had 9.0 mmHg greater systolic BP and 2.3-fold odds of hypertension, compared with individuals in the bottom quartile. These findings were replicated in an external cohort of FHS Offspring participants.

The upstream initiation of inflammatory activity in humans is governed mainly by substrates and products of polyunsaturated ω-3 and ω-6 20-carbon fatty acids.[7,22] Termed eicosanoids, the small molecule derivatives of arachidonic acid and other polyunsaturated fatty acids include prostanoids, leukotrienes, EETs, and HETEs serving as both activators and suppressors of systemic inflammatory activity.[23,24] The majority of research on inflammation in humans has focused on downstream markers of inflammatory activity such as cytokines and acute phase reactants. Recent work by us and others has shown that chronic elevation in these downstream markers is associated with a variety of cardiovascular disease risk traits and outcomes.[25,26] In particular, several cross-sectional and prospective studies in humans have found an association of plasma downstream low-grade inflammation markers, such as interleukin-6, intercellular adhesion molecule-1, C-reactive protein, and tumor necrosis factor alpha, with arterial stiffness and hypertension.[27–33]. Although downstream markers of inflammation are associated with hypertension and a variety of cardiovascular disease outcomes, evidence for a clinically important, causal role of these biomarkers has been mixed.[34] In addition, despite

inflammation being pivotal in the development of atherosclerosis and certain medications with anti-inflammatory properties clearly reduce cardiovascular disease risk, the extent to which any given inflammatory pathway warrants attention as a direct target of therapy has yet to be proven.[35] Such results have now led experts to suggest that, where inflammation is concerned, causative actors could be upstream.[34]

This study is the first to comprehensively examine the association between eicosanoids and BP in humans. Prior studies with study samples consisting of tens of hypertensive subjects with a panel of a few, mainly cytochrome P450 pathway eicosanoids have demonstrated that eicosanoids, in general, affect regulation of renal function, vascular tone, and the development of hypertension.[12,36–39] Our results from a large, population-based sample demonstrate that a large number of eicosanoid species are related to BP in both a positive and negative way. In addition, we demonstrate that distinct eicosanoid profiles are related to a >2-fold increase in odds of hypertension.

Previous studies have suggested that several eicosanoids that were included in the six-eicosanoid risk score in our study regulate BP. First, the cytochrome P450 pathway metabolizes arachidonic acid to several eicosanoids, including 20-HETE and EETs. Several prior studies have shown that 20-HETE is critical in BP regulation.[8] In addition, EETs provide cardio- and renoprotective effects in chronic kidney disease. Particularly, 5,6-EET, which was positively associated with BP in our study, is known to modulate vascular tone and to increase pulmonary artery pressure in animal models.[41,42] Second, 12-HETE, a product of arachidonic acid metabolism through the 12-lipoxygenase pathway that was linked to increased BP in our study, strengthens the effect of angiotensin II and

associates with renal fibrosis and prevalent coronary artery disease.[43,44] Third, cyclooxygenase-derived prostanoids, which include 11-dehydro-2,3-dinor-TXB$_2$, modulate renal vasodilatation, natriuretic mediator excretion, and BP during high salt diet.[45–47] 11-dehydro-2,3-dinor-TXB$_2$ has also been associated in clinical studies with thrombogenesis, pregnancy-induced hypertension, and cardiovascular events.[48–50] In addition to these eicosanoid compounds, adrenic acid and 12-HHTrE were positively correlated with BP in our study sample. Adrenic acid is a polyunsaturated 22-carbon fatty acid and mainly a substrate of eicosanoid production.[51] 12-HHTrE is a lipoxygenase metabolite and nonenzymatic degradation product of prostanoids thromboxane A2 and prostaglandin H2 that has vasoconstrictive effects.[52,53] Given the findings from our study and from previous experimental trials, these results provide a strong biological basis on how eicosanoids affect human BP regulation through several different mechanisms.

Our study has several strengths, such as an unselected population sample, external replication of our results, and availability of a large number of eicosanoids. However, our results must be interpreted in the context of potential limitations. First, LC-MS is a highly sensitive method for assessing circulating metabolites. Therefore, only four of the six eicosanoids that remained in the final forward-selection regression model in FINRISK were observed in FHS samples. However, our results suggest that, in general, the whole family of eicosanoid metabolites is strongly related to BP regulation instead of only select eicosanoids. Second, the exact identity of several of the eicosanoids we observed remains unknown. However, we have previously demonstrated that these signals are highly consistent with known and putative eicosanoids and related oxylipins in human plasma.[14] Third, two of the six eicosanoids in our risk profile were not detected in FHS. Fourth, due

to the cross-sectional and observational nature of our study, no definitive conclusions on causality can be made.

In conclusion, plasma eicosanoids demonstrate strong associations with BP in the general population and differences between eicosanoid profiles are found between normotensive and hypertensive participants. Intriguingly, although most of the associations were positive, we observed specific protective molecules as well as harmful molecules. Thus, in addition to improving hypertension risk prediction, eicosanoids may offer new insights regarding pathogenesis of hypertension and related adverse outcomes, as well as serve as new targets for therapeutic intervention.

Acknowledgments

We thank the participants and staff of the FINRISK 2002 and FHS.

Sources of Funding

This work was supported by the Emil Aaltonen Foundation (TN), the Paavo Nurmi Foundation (TN), the Finnish Medical Foundation (TN), the Academy of Finland (grant n:o 321351 to TN; 295741, 307127 to LL, 321356 to ASH), Ellison Foundation (SC) and the National Heart, Lung and Blood Institute's Framingham Heart Study (contracts N01HC25195 and HHSN268201500001I), and the following National Institutes of Health grants: R01HL093328 (RSV), R01HL107385 (RSV), R01HL126136 (RSV), R00HL107642 (SC), R01HL131532 (SC), R01HL134168 (SC, MJ), R01HL143227 (SC, MJ), R01ES027595 (MJ, SC), and K01DK116917 (JDW). The funders play no role in the design of the study; the collection, analysis, and interpretation of the data; and the decision to

approve publication of the finished manuscript. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Disclosures

None

References

1. Carretero Oscar A., Oparil Suzanne. Essential Hypertension. *Circulation*. 2000;101:329–335.

2. Cavalcante JL, Lima JAC, Redheuil A, Al-Mallah MH. Aortic Stiffness: Current Understanding and Future Directions. *J Am Coll Cardiol*. 2011;57:1511–1522.

3. Harizi H, Corcuff J-B, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. *Trends Mol Med*. 2008;14:461–469.

4. Fan F, Muroya Y, Roman RJ. Cytochrome P450 eicosanoids in hypertension and renal disease. *Curr Opin Nephrol Hypertens*. 2015;24:37–46.

5. Nasjletti Alberto. The Role of Eicosanoids in Angiotensin-Dependent Hypertension. *Hypertension*. 1998;31:194–200.

6. Capdevila J, Wang W. Role of cytochrome P450 epoxygenase in regulating renal membrane transport and hypertension. *Curr Opin Nephrol Hypertens*. 2013;22:163–169.

7. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. *Br J Pharmacol*. 2019;176:1038–1050.

8. Roman RJ, Fan F. 20-HETE: Hypertension and Beyond. *Hypertens Dallas Tex 1979*. 2018;72:12–18.

9. Imig JD. Epoxyeicosatrienoic Acids, Hypertension, and Kidney Injury. *Hypertension*. 2015;65:476–482.

10. Sun D, Cuevas AJ, Gotlinger K, Hwang SH, Hammock BD, Schwartzman ML, Huang A. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure. *Am J Physiol Heart Circ Physiol*. 2014;306:H1146-1153.

11. Kujal P, Chábová VČ, Škaroupková P, Husková Z, Vernerová Z, Kramer HJ, Walkowska A, Kompanowska-Jezierska E, Sadowski J, Kitada K, Nishiyama A, Hwang SH, Hammock BD, Imig JD, Červenka L. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. *Clin Exp Pharmacol Physiol*. 2014;41:227–237.

12. Ward NC, Tsai I-J, Barden A, van Bockxmeer FM, Puddey IB, Hodgson JM, Croft KD. A single nucleotide polymorphism in the CYP4F2 but not CYP4A11 gene is associated with increased 20-HETE excretion and blood pressure. *Hypertens Dallas Tex 1979*. 2008;51:1393–1398.

13. Lagerborg KA, Watrous JD, Cheng S, Jain M. High-Throughput Measure of Bioactive Lipids Using Non-targeted Mass Spectrometry. *Methods Mol Biol Clifton NJ*. 2019;1862:17–35.

14. Watrous JD, Niiranen TJ, Lagerborg KA, Henglin M, Xu Y-J, Rong J, Sharma S, Vasan RS, Larson MG, Armando A, Mora S, Quehenberger O, Dennis EA, Cheng S, Jain M. Directed Non-targeted Mass Spectrometry and Chemical Networking for Discovery of Eicosanoids and Related Oxylipins. *Cell Chem Biol*. 2019;26:433-442.e4.

15. Borodulin K, Tolonen H, Jousilahti P, Jula A, Juolevi A, Koskinen S, Kuulasmaa K, Laatikainen T, Männistö S, Peltonen M, Perola M, Puska P, Salomaa V, Sundvall J,

Virtanen SM, Vartiainen E. Cohort Profile: The National FINRISK Study. *Int J Epidemiol*. 2017. doi:10.1093/ije/dyx239.

16. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. *Am J Epidemiol*. 1979;110:281–290.

17. International Statistical Classification of Diseases version 10 (in Finnish). Terveyden ja hyvinvoinnin laitos (THL); 2011. Available at http://www.julkari.fi/handle/10024/80324. Accessed October 16, 2019.

18. Etymologia: Bonferroni Correction - Volume 21, Number 2—February 2015 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2102.et2102.

19. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. *Nat Med*. 2011;17:448–453.

20. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available at https://www.R-project.org/.

21. Palmu J, Lahti L, Niiranen T. eicosanoidsbp: v1.0. 2020. doi:10.5281/zenodo.3604123.

22. Khanapure SP, Garvey DS, Janero DR, Letts LG. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. *Curr Top Med Chem*. 2007;7:311–340.

23. Elshenawy O, Shoieb S, Mohamed A, El-Kadi A. Clinical Implications of 20-Hydroxyeicosatetraenoic Acid in the Kidney, Liver, Lung and Brain: An Emerging Therapeutic Target. *Pharmaceutics*. 2017;9:9.

24. Roman RJ. P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function. *Physiol Rev*. 2002;82:131–185.

25. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. *Thromb Haemost*. 2006;95:511–518.

26. IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjærg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AAM, Trip MD, Steri M, Witteman JCM, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundström J, Wassertheil-Smoller S, Mellström D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith G, de Bakker PIW, O'Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson J-O, Ohlsson C, Tivesten Å, Ljunggren Ö, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJP, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall

AH, Ridker PM, Hólm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, Danesh J. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. *Lancet Lond Engl*. 2012;379:1205–1213.

27. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. *Hypertens Dallas Tex 1979*. 2001;38:399–403.

28. Lakoski SG, Cushman M, Palmas W, Blumenthal R, D'Agostino RB, Herrington DM. The relationship between blood pressure and C-reactive protein in the Multi-Ethnic Study of Atherosclerosis (MESA). *J Am Coll Cardiol*. 2005;46:1869–1874.

29. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. *Hypertens Dallas Tex 1979*. 2005;46:1118–1122.

30. Sesso HD, Jiménez MC, Wang L, Ridker PM, Buring JE, Gaziano JM. Plasma Inflammatory Markers and the Risk of Developing Hypertension in Men. *J Am Heart Assoc*. 2015;4:e001802.

31. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. *JAMA*. 2003;290:2945–2951.

32. McEniery CM, Spratt M, Munnery M, Yarnell J, Lowe GD, Rumley A, Gallacher J, Ben-Shlomo Y, Cockcroft JR, Wilkinson IB. An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. *Hypertens Dallas Tex 1979*. 2010;56:36–43.

33. Chuang S-Y, Hsu P-F, Chang H-Y, Bai C-H, Yeh W-T, Pan H-W. C-reactive protein predicts systolic blood pressure and pulse pressure but not diastolic blood pressure: the Cardiovascular Disease Risk Factors Two-Township Study. *Am J Hypertens*. 2013;26:657–664.

34. Brunner EJ, Kivimäki M, Witte DR, Lawlor DA, Davey Smith G, Cooper JA, Miller M, Lowe GDO, Rumley A, Casas JP, Shah T, Humphries SE, Hingorani AD, Marmot MG, Timpson NJ, Kumari M. Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. *PLoS Med*. 2008;5:e155.

35. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. *Lancet Lond Engl*. 2018;391:319–328.

36. Laffer CL, Laniado-Schwartzman M, Wang M-H, Nasjletti A, Elijovich F. Differential regulation of natriuresis by 20-hydroxyeicosatetraenoic Acid in human salt-sensitive versus salt-resistant hypertension. *Circulation*. 2003;107:574–578.

37. Ward NC, Puddey IB, Hodgson JM, Beilin LJ, Croft KD. Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. *Free Radic Biol Med*. 2005;38:1032–1036.

38. Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, Magagna A, Virdis A, Salvetti A. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. *J Am Coll Cardiol*. 2006;48:508–515.

39. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. *Hypertens Dallas Tex 1979*. 2008;51:1379–1385.

40. Zordoky BNM, El-Kadi AOS. Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. *Pharmacol Ther*. 2010;125:446–463.

41. Kandhi S, Froogh G, Qin J, Luo M, Wolin MS, Huang A, Sun D. EETs Elicit Direct Increases in Pulmonary Arterial Pressure in Mice. *Am J Hypertens*. 2016;29:598–604.

42. Cazade M, Bidaud I, Hansen PB, Lory P, Chemin J. 5,6-EET potently inhibits T-type calcium channels: implication in the regulation of the vascular tone. *Pflüg Arch - Eur J Physiol*. 2014;466:1759–1768.

43. Zhang HJ, Sun CH, Kuang HY, Jiang XY, Liu HL, Hua WF, Liu ZJ, Zhou H, Sui H, Qi R. 12S-hydroxyeicosatetraenoic acid levels link to coronary artery disease in Type 2 diabetic patients. *J Endocrinol Invest*. 2013;36:385–389.

44. Yiu SS, Zhao X, Inscho EW, Imig JD. 12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. *J Lipid Res*. 2003;44:2391–2399.

45. Watanabe H, Katoh T, Eiro M, Iwamoto M, Ushikubi F, Narumiya S, Watanabe T. Effects of salt loading on blood pressure in mice lacking the prostanoid receptor gene. *Circ J Off J Jpn Circ Soc*. 2005;69:124–126.

46. Yu Y, Stubbe J, Ibrahim S, Song W, Symth EM, Funk CD, FitzGerald GA. COX-2 Dependent Prostacyclin Formation and Blood Pressure Homeostasis: Targeted Exchange of COX Isoforms in Mice. *Circ Res*. 2010;106:337.

47. Snowden S, Nelson R. The effects of nonsteroidal anti-inflammatory drugs on blood pressure in hypertensive patients. *Cardiol Rev*. 2011;19:184–191.

48. DeFilippis AP, Oloyede OS, Andrikopoulou E, Saenger AK, Palachuvattil JM, Fasoro YA, Guallar E, Blumenthal RS, Kickler TS, Jaffe AS, Gerstenblith G, Schulman SP, Rade JJ. Thromboxane A(2) generation, in the absence of platelet COX-1 activity, in patients with and without atherothrombotic myocardial infarction. *Circ J Off J Jpn Circ Soc*. 2013;77:2786–2792.

49. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak K-H, Easton JD, Hamm C, Hu T, Fox KAA, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. *Circulation*. 2008;118:1705–1712.

50. Fitzgerald DJ, Rocki W, Murray R, Mayo G, FitzGerald GA. Thromboxane A2 synthesis in pregnancy-induced hypertension. *Lancet Lond Engl*. 1990;335:751–754.

51. Kopf PG, Zhang DX, Gauthier KM, Nithipatikom K, Yi X-Y, Falck JR, Campbell WB. Adrenic acid metabolites as endogenous endothelium-derived and zona glomerulosa-derived hyperpolarizing factors. *Hypertens Dallas Tex 1979*. 2010;55:547–554.

52. Mezei Z, Kis B, Gecse Á, Telegdy G, Ábrahám G, Sonkodi S. Platelet eicosanoids and the effect of captopril in blood pressure regulation. *Eur J Pharmacol*. 1997;340:67–73.

53. Maddipati KR, Romero R, Chaiworapongsa T, Zhou S-L, Xu Z, Tarca AL, Kusanovic JP, Munoz H, Honn KV. Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor. *FASEB J*. 2014;28:4835–4846.

Figure Legends

Figure 1. Manhattan plot for associations between eicosanoids and systolic blood pressure in FINRISK 2002.

Figure 2. Correlation matrix for the 187 plasma eicosanoids related to systolic blood pressure in FINRISK 2002.

Figure 3. The associations between the six eicosanoids independently related to systolic

BP in FINRISK and replication results in FHS.

Figure 4. The association between a 6-eicosanoid risk score and systolic blood pressure

in FINRISK and FHS.

Figure 5. The association between a 6-eicosanoid risk score and hypertension in FINRISK

and FHS.

Tables

Table 1. Characteristics of the discovery (FINRISK) and replication (FHS) samples.

Characteristics	FINRISK 2002	FHS
N	8099	2859
Age, y (SD)	48.0 (13.1)	66.3 (8.9)
Female, N (%)	4300 (53.1)	1564 (54.7)
BMI, kg/m² (SD)	26.9 (4.7)	28.3 (5.4)
Systolic blood pressure, mmHg (SD)	135.1 (20.0)	128.5 (17.2)
Diastolic blood pressure, mmHg (SD)	79.0 (11.3)	73.4 (10.1)
Pulse pressure, mmHg (SD)	56.1 (16.1)	55.1 (16.0)
Mean arterial pressure, mmHg (SD)	97.7 (12.7)	91.8 (10.5)
Hypertension, N (%)	3567 (44.0)	1673 (58.5)
Antihypertensive medication, N (%)	1177 (14.5)	1389 (48.6)
Current smoker, N (%)	2097 (25.9)	256 (9.0)
Diabetes mellitus, N (%)	446 (5.5)	393 (13.7)

Continuous variables are presented as mean (standard deviation). Categorical variables reported as absolute and relative frequencies. BMI, body mass index; FHS, Framingham Heart Study.

Figure 1. Manhattan plot for associations between eicosanoids and systolic blood pressure in FINRISK 2002.

A significant association was observed for 187 of the 545 eicosanoids. Positive correlations are denoted in red, negative in blue and insignificant in gray. Eicosanoids are ordered by the value of mass to charge ratio (m/z). Dashed line represents the Bonferroni corrected (p=0.05/545) level of significance. Analyses are adjusted for age, sex, BMI, current smoking, diabetes, antihypertensive medication, and batch.

Figure 2. Correlation matrix for the 187 plasma eicosanoids related to systolic blood pressure in FINRISK 2002.

Relations between eicosanoids were calculated using Spearman correlation and ordered using hierarchical cluster analysis with complete linkage method. Only eicosanoids related to systolic blood pressure were included in the correlation matrix. Asterisk denotes the six eicosanoid species in our eicosanoid profile (**Figure 3**).

Figure 3. The associations between the six eicosanoids independently related to systolic BP in FINRISK and replication results in FHS.

Eicosanoid	FINRISK β (95% CI)	FHS β (95% CI)
11-dehydro-2,3-dinor-TXB2	1.60 (1.20–2.01)	
12-HHTrE	1.12 (0.74–1.50)	1.38 (0.77–1.98)
295.2279/4.89 (putative eicosanoid)	1.96 (1.58–2.34)	
5,6-EET	2.74 (2.37–3.11)	1.42 (0.82–2.02)
Adrenic Acid	2.77 (2.37–3.16)	1.26 (0.63–1.88)
Tetranor-12(R)-HETE	1.43 (1.05–1.81)	1.89 (1.28–2.49)

Associations are expressed as increase in systolic blood pressure by 1-SD increase in eicosanoid abundance. All models were adjusted for age, sex, BMI, current smoking, diabetes, antihypertensive medication, and technical covariate. Two of the six eicosanoids observed in FINRISK were not observed in FHS plasma samples. A potential alternative identity for 5,6-EET is 8,9-EET. One eicosanoid (retention time/mass-to-charge ratio of 295.2279/4.89) remains unidentified. FHS, Framingham Heart Study; EET, epoxyeicosatrienoic acid; HHTrE, hydroxyheptadecatrenoic acid; TXB2, thromboxane B2; HETE, hexadecatrienoic acid.

Figure 4. The association between a 6-eicosanoid risk score and systolic blood pressure in FINRISK and FHS.

We calculated eicosanoid risk score for each participant according to the formula $\beta_1 X_1 + \beta_2 X_2 + ... + \beta_n X_n$, with X_n denoting the standardized value for the nth eicosanoid abundance, and β_n denoting the regression coefficient from the regression model containing the indicated eicosanoids. Analyses are adjusted for age, sex, BMI, current smoking, diabetes and antihypertensive medication and batch. FHS, Framingham Heart Study; BP, blood pressure.

Figure 5. The association between a 6-eicosanoid risk score and hypertension in FINRISK and FHS.

We calculated eicosanoid risk score for each participant according to the formula $\beta_1 X_1 + \beta_2 X_2 + ... + \beta_n X_n$ with X_n denoting the standardized value for the nth eicosanoid abundance, and β_n denoting the regression coefficient from the regression model in FINRISK containing the indicated eicosanoids. Multivariable analyses are adjusted for age, sex, BMI, current smoking, diabetes and antihypertensive medication and batch. FHS, Framingham Heart Study; BP, blood pressure.

Data Supplement

Figure S1. Correlation matrix with labels for the 187 plasma eicosanoids related to systolic blood pressure in FINRISK 2002.

Relations between eicosanoids were calculated using Spearman correlation and ordered using hierarchical cluster analysis with complete linkage method. Only eicosanoids related to systolic blood pressure were included in the correlation matrix. Asterisk denotes the six eicosanoids species in our eicosanoid profile (**Figure 3**).

Table S1. Association of eicosanoids with mean arterial pressure, systolic blood pressure, diastolic blood pressure, pulse pressure and hypertension in FINRISK 2002.

M/Z	RT	Systolic BP		Diastolic BP		MAP		Pulse pressure		Hypertension	
		β±SE	p	β±SE	p	β±SE	p	β±SE	p	β±SE	p
227.2011	6.3517	2.27±0.20	7e-30	0.86±0.12	8e-13	1.33±0.13	2e-25	1.41±0.17	3e-16	1.27±0.03	2e-15
241.2185	6.4318	1.17±0.20	3e-09			0.64±0.13	4e-07	0.80±0.17	3e-06	1.14±0.03	9e-06
253.2166	6.4540	2.03±0.21	6e-23	0.94±0.12	3e-14	1.30±0.13	4e-23	1.09±0.18	7e-10	1.22±0.03	1e-10
253.2170	6.5120	1.48±0.20	3e-13	0.66±0.12	5e-08	0.93±0.13	5e-13	0.82±0.17	3e-06	1.18±0.03	3e-08
253.2175	6.5583	2.33±0.20	1e-30	0.96±0.12	2e-15	1.42±0.13	5e-28	1.37±0.17	5e-15	1.28±0.03	1e-15
255.2329	6.6107	1.23±0.20	7e-10			0.67±0.13	2e-07	0.84±0.17	9e-07	1.17±0.03	6e-08
265.1808	3.6322	1.27±0.19	6e-11	0.54±0.12	3e-06	0.78±0.12	3e-10	0.73±0.17	1e-05	1.14±0.03	1e-05
265.1810	3.5705	1.43±0.19	2e-13	0.64±0.12	3e-08	0.90±0.12	3e-13	0.78±0.17	3e-06	1.14±0.03	4e-06
267.1968	3.4410	1.24±0.20	6e-10			0.50±0.13	9e-05	1.10±0.17	1e-10		
267.1968	3.4780	2.18±0.19	3e-29	0.70±0.12	2e-09	1.19±0.12	7e-22	1.49±0.17	6e-19	1.29±0.03	4e-17
267.1968	3.5767							0.85±0.17	5e-07		
267.2326	6.6168	1.84±0.20	3e-19	0.67±0.12	4e-08	1.06±0.13	5e-16	1.17±0.18	4e-11	1.23±0.03	1e-11
267.2331	6.5490	1.50±0.20	4e-14	0.63±0.12	1e-07	0.92±0.13	4e-13	0.87±0.17	4e-07	1.16±0.03	4e-07
267.2332	6.4997	1.53±0.21	1e-13	0.75±0.12	1e-09	1.01±0.13	2e-14	0.78±0.18	1e-05	1.19±0.03	2e-08
269.2125	4.7668	2.10±0.20	1e-26	0.85±0.12	8e-13	1.26±0.13	9e-24	1.26±0.17	1e-13	1.26±0.03	2e-15
269.2485	6.6847	1.19±0.20	2e-09			0.61±0.13	1e-06	0.87±0.17	4e-07	1.15±0.03	4e-06
269.2524	6.5937	1.57±0.21	3e-14	0.53±0.12	2e-05	0.87±0.13	3e-11	1.04±0.18	5e-09	1.19±0.03	1e-08
275.2018	5.8892	1.16±0.19	2e-09			0.65±0.12	2e-07	0.77±0.17	4e-06	1.15±0.03	2e-05
277.2173	6.3486	1.79±0.20	2e-19	0.76±0.12	2e-10	1.10±0.13	4e-18	1.03±0.17	1e-09	1.21±0.03	6e-11
277.2176	6.2962	1.49±0.20	4e-14	0.53±0.12	7e-06	0.85±0.13	1e-11	0.96±0.17	1e-08	1.18±0.03	2e-08
277.2179	6.4056	2.39±0.20	3e-31	0.96±0.12	6e-15	1.44±0.13	6e-28	1.43±0.18	6e-16	1.25±0.03	2e-13
279.1966	3.7247	1.12±0.20	1e-08	0.52±0.12	8e-06	0.72±0.12	7e-09			1.13±0.03	2e-05
279.2329	6.5058	1.45±0.20	9e-13	0.57±0.12	2e-06	0.87±0.13	2e-11	0.88±0.17	5e-07	1.15±0.03	5e-06
279.2330	6.4750	1.02±0.20	3e-07			0.59±0.13	3e-06				
279.2330	6.5552	1.70±0.20	2e-17	0.60±0.12	5e-07	0.97±0.13	4e-14	1.10±0.17	2e-10	1.16±0.03	7e-07
281.2487	6.6847	2.11±0.20	5e-26	0.92±0.12	2e-14	1.32±0.13	7e-25	1.20±0.17	4e-12	1.29±0.03	4e-17
281.2488	6.5613	1.51±0.20	1e-14	0.62±0.12	1e-07	0.92±0.12	2e-13	0.89±0.17	1e-07	1.20±0.03	3e-10
283.2643	6.6168	0.82±0.19	3e-05			0.54±0.12	1e-05				
283.2643	6.7124	2.02±0.24	1e-17	0.73±0.14	3e-07	1.16±0.15	2e-14	1.29±0.20	2e-10	1.22±0.03	2e-08
291.1963	4.2427	0.94±0.20	3e-06			0.57±0.13	9e-06				
291.1967	3.9898	1.17±0.19	2e-09					1.03±0.17	8e-10		
291.1968	4.7360	2.35±0.19	6e-35	0.98±0.11	8e-18	1.44±0.12	3e-32	1.37±0.16	8e-17	1.27±0.03	2e-16
291.1969	4.6805	1.70±0.19	7e-19	0.62±0.11	7e-08	0.98±0.12	1e-15	1.08±0.16	5e-11	1.15±0.03	7e-07
293.2087	5.1060	1.49±0.19	8e-15	0.68±0.11	3e-09	0.95±0.12	7e-15	0.81±0.17	1e-06	1.17±0.03	3e-08
293.2098	4.0577	0.81±0.19	3e-05					0.71±0.17	2e-05		
293.2109	4.3136							0.80±0.17	1e-06		
293.2111	4.6898	1.60±0.19	9e-17	0.48±0.11	2e-05	0.86±0.12	3e-12	1.11±0.16	2e-11	1.16±0.03	1e-07
293.2123	3.8603							0.70±0.17	2e-05		

M/Z	RT	Systolic BP β±SE	p	Diastolic BP β±SE	p	MAP β±SE	p	Pulse pressure β±SE	p	Hypertension β±SE	p
293.2123	3.9837	0.96±0.19	7e-07					0.79±0.17	2e-06	1.13±0.03	2e-05
293.2123	4.8100	1.62±0.19	5e-17			0.82±0.12	3e-11	1.20±0.17	5e-13	1.16±0.03	2e-07
293.2124	3.9343	1.39±0.20	2e-12			0.74±0.13	6e-09	0.98±0.17	9e-09	1.16±0.03	7e-07
293.2124	4.1687							0.66±0.17	6e-05		
293.2124	4.4030							0.78±0.17	2e-06		
293.2124	4.4585	0.75±0.19	9e-05					0.72±0.16	1e-05		
293.2124	4.5017	1.06±0.20	7e-08			0.50±0.13	6e-05	0.83±0.17	9e-07		
293.2125	4.3537	1.00±0.19	3e-07					1.03±0.17	8e-10	1.12±0.03	4e-05
293.2125	4.7607	1.91±0.19	4e-23	0.54±0.12	3e-06	1.00±0.12	7e-16	1.38±0.17	1e-16	1.20±0.03	2e-10
293.2125	5.0382	2.35±0.19	3e-34	1.03±0.12	6e-19	1.47±0.12	8e-33	1.32±0.17	2e-15	1.29±0.03	1e-18
295.2279	4.8902	1.96±0.19	5e-24			0.95±0.12	1e-14	1.51±0.17	1e-19	1.25±0.03	5e-15
295.2279	5.6055	1.68±0.19	3e-18	0.48±0.12	3e-05	0.88±0.12	9e-13	1.20±0.17	4e-13	1.19±0.03	4e-10
295.2280	3.9312	1.70±0.19	8e-19			0.78±0.12	2e-10	1.39±0.17	6e-17	1.21±0.03	2e-11
295.2280	4.4400							0.68±0.17	5e-05		
295.2280	4.5017	1.91±0.19	8e-23	0.57±0.12	1e-06	1.01±0.12	3e-16	1.34±0.17	9e-16	1.26±0.03	2e-15
295.2280	5.0690	1.36±0.19	2e-12					1.32±0.16	1e-15	1.16±0.03	5e-08
295.2281	4.6188	1.16±0.19	2e-09					1.07±0.17	2e-10		
295.2281	4.6682	1.94±0.19	1e-23	0.72±0.12	6e-10	1.12±0.12	9e-20	1.22±0.17	2e-13	1.22±0.03	7e-13
297.2437	4.6404	1.61±0.19	3e-17	0.70±0.11	1e-09	1.00±0.12	2e-16	0.92±0.16	3e-08	1.18±0.03	3e-09
297.2437	4.7237	1.76±0.21	3e-17	0.74±0.12	3e-09	1.08±0.13	4e-16	1.02±0.18	1e-08	1.20±0.03	1e-08
299.1869	2.6578	0.86±0.19	9e-06			0.55±0.12	8e-06				
299.2595	5.3974	1.83±0.19	2e-21	0.78±0.11	1e-11	1.13±0.12	3e-20	1.05±0.16	2e-10	1.22±0.03	3e-12
301.2177	6.2530	1.32±0.20	6e-11	0.57±0.12	3e-06	0.82±0.13	2e-10	0.76±0.17	1e-05	1.16±0.03	7e-07
303.2303	6.3933	1.67±0.20	5e-17	0.79±0.12	4e-11	1.08±0.13	2e-17	0.88±0.17	3e-07	1.22±0.03	7e-10
303.2329	6.4442	2.07±0.20	5e-26	0.77±0.12	5e-11	1.20±0.12	7e-22	1.30±0.17	2e-14	1.25±0.03	3e-14
303.2332	6.5367	1.05±0.20	2e-07			0.57±0.13	6e-06	0.71±0.17	3e-05	1.13±0.03	1e-05
305.2437	6.4627	1.18±0.20	5e-09			0.62±0.13	1e-06	0.84±0.17	1e-06	1.13±0.03	3e-05
305.2495	6.6137	1.74±0.20	4e-18	0.70±0.12	7e-09	1.04±0.13	3e-16	1.05±0.17	1e-09	1.21±0.03	2e-10
305.2518	6.4997	2.05±0.20	4e-24	0.76±0.12	4e-10	1.19±0.13	4e-20	1.29±0.17	1e-13	1.26±0.03	2e-14
307.1890	2.6208			0.52±0.12	1e-05	0.53±0.13	3e-05				
307.1899	2.3279	1.24±0.21	6e-09			0.59±0.14	1e-05	0.97±0.18	1e-07	1.15±0.03	8e-06
307.1905	2.4852	1.23±0.19	2e-10	0.51±0.12	1e-05	0.75±0.12	1e-09	0.73±0.17	1e-05		
307.1912	2.5222	1.74±0.19	3e-19	0.82±0.12	2e-12	1.12±0.12	1e-19	0.93±0.17	3e-08	1.18±0.03	5e-09
307.2644	6.5675	2.17±0.20	7e-27	0.74±0.12	1e-09	1.22±0.13	4e-21	1.43±0.17	2e-16	1.27±0.03	2e-15
307.2645	6.6168	2.01±0.20	1e-24	0.78±0.12	3e-11	1.19±0.12	2e-21	1.23±0.17	3e-13	1.25±0.03	3e-14
307.2645	6.6785	2.04±0.20	5e-25	0.76±0.12	1e-10	1.19±0.13	5e-21	1.28±0.17	5e-14	1.26±0.03	3e-15
309.2071	3.1327			-0.55±0.12	2e-06						
309.2074	4.2797					-0.52±0.12	3e-05				
309.2078	3.3238	1.19±0.19	8e-10			0.67±0.12	6e-08	0.78±0.17	3e-06	1.13±0.03	8e-06
309.2094	3.1851			-0.51±0.12	1e-05						
309.2103	2.8120	1.00±0.19	2e-07					0.80±0.16	1e-06		
309.2798	6.6353	1.66±0.20	2e-16	0.63±0.12	2e-07	0.97±0.13	4e-14	1.03±0.17	3e-09	1.20±0.03	2e-09

M/Z	RT	Systolic BP β±SE	p	Diastolic BP β±SE	p	MAP β±SE	p	Pulse pressure β±SE	p	Hypertension β±SE	p
309.2800	6.6662	1.30±0.20	2e-11	0.51±0.12	1e-05	0.78±0.12	4e-10	0.79±0.17	3e-06	1.17±0.03	4e-08
309.2800	6.6970	1.59±0.20	6e-16	0.67±0.12	1e-08	0.98±0.13	7e-15	0.92±0.17	6e-08	1.22±0.03	1e-11
311.2231	2.9230			-0.60±0.11	2e-07			0.68±0.17	4e-05		
311.2231	2.9600			-0.47±0.11	3e-05						
311.2957	6.6908	0.82±0.19	3e-05								
311.2957	6.7217									1.14±0.03	5e-06
313.2386	3.5643	0.92±0.19	2e-06					0.75±0.16	6e-06		
313.2387	3.2313	1.88±0.19	1e-22	0.48±0.11	3e-05	0.94±0.12	1e-14	1.40±0.16	3e-17	1.24±0.03	2e-10
313.2388	3.3300							0.80±0.17	2e-06		
317.2109	4.3413	0.88±0.20	7e-06	0.49±0.12	3e-05	0.62±0.13	7e-07				
317.2122	3.6753	1.77±0.19	1e-19	0.61±0.12	2e-07	0.99±0.12	1e-15	1.16±0.17	5e-12	1.19±0.03	2e-09
317.2122	4.0145	1.32±0.19	5e-12			0.71±0.12	9e-09	0.93±0.17	2e-08	1.18±0.03	3e-07
317.2123	4.9148	1.39±0.20	5e-12	0.58±0.12	1e-06	0.85±0.13	3e-11	0.81±0.17	3e-06	1.16±0.03	4e-07
317.2124	4.1378	1.20±0.19	4e-10			0.68±0.12	3e-08	0.78±0.17	2e-06	1.15±0.03	7e-07
317.2124	5.3342	1.89±0.20	2e-21	0.83±0.12	3e-12	1.19±0.13	1e-20	1.06±0.17	6e-10	1.22±0.03	3e-11
317.2125	3.7185	1.68±0.19	7e-18	0.61±0.12	2e-07	0.96±0.12	8e-15	1.07±0.17	2e-10	1.18±0.03	4e-09
317.2125	5.2663	2.21±0.20	2e-28	1.07±0.12	3e-19	1.45±0.13	4e-30	1.14±0.17	4e-11	1.30±0.03	4e-18
317.2126	4.9580	1.01±0.20	4e-07	0.50±0.12	2e-05	0.67±0.13	1e-07				
317.2157	5.3897	1.28±0.20	6e-11	0.50±0.12	2e-05	0.76±0.12	1e-09	0.78±0.17	3e-06	1.18±0.03	6e-08
319.2224	4.0577	1.60±0.19	7e-17	0.50±0.11	1e-05	0.87±0.12	1e-12	1.10±0.16	3e-11	1.18±0.03	1e-09
319.2271	4.5818	1.21±0.19	5e-10			0.70±0.12	2e-08	0.77±0.17	5e-06	1.14±0.03	4e-06
319.2276	4.5017	1.20±0.19	3e-10	0.66±0.11	9e-09	0.84±0.12	6e-12				
319.2279	5.7288	2.20±0.19	2e-30	0.98±0.11	1e-17	1.39±0.12	7e-30	1.22±0.16	2e-13	1.29±0.03	2e-19
319.2280	5.6733	2.74±0.19	1e-46	1.19±0.11	3e-25	1.71±0.12	1e-44	1.55±0.16	5e-21	1.35±0.03	7e-25
319.2281	4.1070	1.70±0.20	5e-18	0.64±0.12	6e-08	0.99±0.13	3e-15	1.06±0.17	3e-10	1.20±0.03	2e-10
319.2281	4.6558	2.23±0.20	8e-30	1.05±0.12	4e-19	1.45±0.12	1e-30	1.18±0.17	4e-12	1.28±0.03	4e-17
319.2281	4.7730	1.37±0.19	8e-13	0.49±0.11	2e-05	0.78±0.12	2e-10	0.88±0.16	8e-08	1.16±0.03	5e-08
319.2281	4.8285	1.29±0.19	2e-11			0.73±0.12	3e-09	0.84±0.16	3e-07	1.14±0.03	2e-06
319.2281	5.0382	1.00±0.19	2e-07	0.49±0.11	2e-05	0.66±0.12	7e-08				
319.2281	5.2910	0.89±0.20	7e-06	0.61±0.12	2e-07	0.70±0.13	2e-08				
319.2288	5.1523	1.41±0.19	3e-13			0.74±0.12	3e-09	1.01±0.17	1e-09	1.19±0.03	2e-10
319.2304	4.8840	1.30±0.19	1e-11	0.61±0.11	1e-07	0.84±0.12	7e-12	0.69±0.16	3e-05	1.16±0.04	2e-05
321.2370	5.6795	1.81±0.25	3e-13	0.63±0.15	2e-05	1.03±0.16	9e-11	1.18±0.21	3e-08	1.23±0.04	4e-08
321.2383	5.1923	0.76±0.19	7e-05								
321.2416	5.7998	1.54±0.19	2e-15	0.96±0.12	7e-17	1.16±0.12	7e-21			1.24±0.03	7e-14
321.2433	4.8593	1.44±0.19	9e-14	0.75±0.12	8e-11	0.98±0.12	2e-15	0.69±0.17	3e-05	1.15±0.03	1e-06
321.2437	4.9025	1.54±0.19	2e-15	0.74±0.12	1e-10	1.01±0.12	4e-16	0.80±0.17	2e-06	1.21±0.03	8e-10
321.2437	4.9827	1.51±0.19	4e-15	0.70±0.11	1e-09	0.97±0.12	3e-15	0.82±0.17	8e-07	1.19±0.04	9e-07
321.2437	5.0813	1.82±0.19	2e-21	0.69±0.11	2e-09	1.07±0.12	3e-18	1.13±0.16	6e-12	1.23±0.03	3e-13
321.2437	6.0526	2.02±0.19	6e-26	0.98±0.11	2e-17	1.32±0.12	2e-27	1.04±0.16	3e-10	1.27±0.03	1e-16
321.2438	5.9508	1.73±0.19	2e-19	0.64±0.11	3e-08	1.00±0.12	3e-16	1.09±0.16	4e-11	1.20±0.03	2e-10
321.2440	4.4153	0.88±0.20	8e-06			0.57±0.13	6e-06				

		Systolic BP		Diastolic BP		MAP		Pulse pressure		Hypertension	
M/Z	RT	β±SE	p	β±SE	p	β±SE	p	β±SE	p	β±SE	p
321.2440	5.3958	2.60±0.19	1e-41	1.21±0.11	1e-25	1.67±0.12	3e-42	1.39±0.17	5e-17	1.31±0.03	8e-22
323.2581	5.4945	1.23±0.19	3e-10			0.56±0.12	8e-06	1.01±0.17	2e-09	1.16±0.03	5e-07
323.2599	5.6733	1.76±0.19	2e-19	0.51±0.12	1e-05	0.93±0.12	9e-14	1.24±0.17	1e-13	1.23±0.03	3e-12
325.2386	5.0258					-0.50±0.12	6e-05				
327.2321	6.4287	2.18±0.21	7e-26	0.97±0.12	5e-15	1.37±0.13	2e-25	1.21±0.18	1e-11	1.27±0.03	3e-14
327.2324	6.4966	1.15±0.20	9e-09			0.66±0.13	3e-07	0.73±0.17	2e-05	1.13±0.03	3e-05
329.2336	2.4235			-0.62±0.11	7e-08	-0.55±0.12	7e-06				
329.2341	2.5653			-0.59±0.12	3e-07	-0.54±0.12	1e-05				
329.2487	6.5058	2.21±0.20	1e-28	0.77±0.12	9e-11	1.25±0.13	7e-23	1.44±0.17	5e-17	1.23±0.03	4e-12
329.2496	6.4596	2.22±0.20	3e-27	0.85±0.12	6e-12	1.31±0.13	3e-23	1.38±0.18	9e-15	1.25±0.03	1e-12
331.1909	2.9766	-1.07±0.19	4e-08			-0.56±0.12	7e-06	-0.76±0.17	5e-06	0.87±0.03	3e-05
331.1918	2.6763	-0.91±0.20	3e-06			-0.60±0.12	2e-06			0.88±0.03	3e-05
331.2653	6.5737	2.14±0.20	2e-27	0.72±0.12	9e-10	1.20±0.13	2e-21	1.42±0.17	8e-17	1.28±0.03	4e-16
331.2679	6.5274	2.77±0.20	1e-42	1.04±0.12	1e-17	1.62±0.13	7e-36	1.73±0.17	4e-23	1.34±0.03	1e-21
333.2047	4.6312	-1.04±0.23	8e-06	-0.75±0.14	7e-08	-0.85±0.15	1e-08			0.86±0.04	8e-05
333.2051	4.3537			-0.48±0.12	4e-05						
333.2075	2.8613									0.84±0.04	8e-05
333.2075	3.2807	-0.76±0.20	9e-05			-0.49±0.12	9e-05				
333.2791	6.6269	2.26±0.20	4e-30	0.95±0.12	2e-15	1.38±0.13	8e-28	1.32±0.17	1e-14	1.30±0.03	1e-17
335.1456	3.8048	1.53±0.20	5e-15			0.70±0.13	3e-08	1.26±0.17	9e-14	1.16±0.03	4e-07
335.2229	3.0710	0.76±0.19	8e-05	0.58±0.12	5e-07	0.64±0.12	2e-07				
335.2231	3.3423	1.23±0.19	1e-10	0.53±0.11	5e-06	0.76±0.12	5e-10	0.71±0.17	2e-05	1.18±0.03	1e-08
335.2231	3.5643	1.40±0.19	6e-13	0.65±0.12	2e-08	0.90±0.12	4e-13	0.74±0.17	8e-06	1.21±0.03	2e-11
335.2911	6.6137	1.66±0.20	3e-17	0.71±0.12	1e-09	1.03±0.12	2e-16	0.94±0.17	2e-08	1.23±0.03	6e-10
335.2961	6.6847	1.05±0.19	5e-08	0.51±0.12	1e-05	0.69±0.12	2e-08			1.19±0.04	5e-06
337.2341	3.0093					0.49±0.12	5e-05				
337.2353	3.9158	1.52±0.19	2e-15	0.47±0.11	5e-05	0.82±0.12	2e-11	1.05±0.16	2e-10	1.17±0.03	2e-08
337.2371	3.0340					0.52±0.12	3e-05				
337.2381	3.5458	1.95±0.20	8e-23	0.47±0.12	8e-05	0.96±0.13	3e-14	1.48±0.17	4e-18	1.25±0.03	2e-13
337.2383	3.6260	1.60±0.20	5e-16	0.47±0.12	8e-05	0.84±0.13	2e-11	1.13±0.17	2e-11	1.21±0.03	9e-11
337.2383	4.1872	1.44±0.19	5e-14	0.53±0.11	4e-06	0.84±0.12	9e-12	0.91±0.16	3e-08	1.18±0.03	7e-09
339.1792	1.7883	1.16±0.20	7e-09					1.10±0.17	2e-10		
339.1799	1.7205	1.60±0.21	1e-14			0.61±0.13	4e-06	1.49±0.18	6e-17	1.16±0.03	2e-06
341.2126	5.2848	1.13±0.20	3e-08			0.51±0.13	8e-05	0.93±0.17	1e-07		
343.2248	4.4400	1.07±0.20	8e-08			0.60±0.13	2e-06	0.70±0.17	5e-05	1.15±0.03	3e-06
343.2256	4.6065	1.09±0.20	3e-08	0.53±0.12	7e-06	0.72±0.13	1e-08				
343.2273	5.3095	1.85±0.19	2e-21			0.90±0.12	5e-13	1.43±0.17	2e-17	1.24±0.03	7e-13
343.2275	4.5263	1.08±0.20	4e-08			0.61±0.12	9e-07	0.70±0.17	4e-05	1.13±0.03	1e-05
343.2278	5.1985	1.11±0.20	2e-08			0.64±0.13	3e-07	0.70±0.17	4e-05	1.15±0.03	6e-06
343.2279	4.7545	1.62±0.19	1e-16	0.56±0.12	2e-06	0.91±0.12	2e-13	1.06±0.17	3e-10	1.22±0.03	7e-12
343.2279	4.9950	2.09±0.19	5e-27	0.58±0.12	8e-07	1.08±0.12	3e-18	1.51±0.17	1e-19	1.27±0.03	4e-15
343.2281	4.6712	1.17±0.19	1e-09			0.66±0.12	8e-08	0.76±0.17	4e-06	1.16±0.03	5e-07

M/Z	RT	Systolic BP		Diastolic BP		MAP		Pulse pressure		Hypertension	
		β±SE	p	β±SE	p	β±SE	p	β±SE	p	β±SE	p
343.2281	5.0752	0.91±0.20	4e-06					0.84±0.17	7e-07		
343.2283	4.3012	1.53±0.20	1e-14	0.61±0.12	3e-07	0.92±0.13	4e-13	0.92±0.17	6e-08	1.18±0.03	9e-09
345.2346	4.6497	1.04±0.20	1e-07			0.61±0.13	1e-06			1.14±0.03	2e-05
345.2355	4.7607	0.90±0.20	4e-06			0.54±0.12	2e-05			1.15±0.03	2e-06
345.2431	4.7113	1.26±0.21	2e-09	0.56±0.13	9e-06	0.79±0.13	3e-09			1.17±0.03	6e-07
345.2435	4.5510	1.85±0.20	7e-21	0.74±0.12	5e-10	1.11±0.13	2e-18	1.12±0.17	6e-11	1.21±0.03	5e-11
345.2435	5.4698	1.68±0.19	4e-18	0.76±0.12	5e-11	1.07±0.12	6e-18	0.92±0.17	3e-08	1.21±0.04	8e-08
345.2437	4.8408	1.08±0.19	3e-08	0.55±0.12	3e-06	0.72±0.12	6e-09			1.12±0.03	6e-05
345.2437	4.9518	1.49±0.19	8e-15	0.59±0.11	3e-07	0.89±0.12	4e-13	0.91±0.17	4e-08	1.19±0.03	7e-10
345.2437	5.3033	1.70±0.19	7e-19	0.56±0.11	1e-06	0.94±0.12	2e-14	1.14±0.16	5e-12	1.21±0.03	1e-10
345.2441	5.0505	0.96±0.20	1e-06					0.74±0.17	1e-05		
347.2590	5.3835	1.54±0.21	2e-13	0.63±0.12	4e-07	0.93±0.13	2e-12	0.90±0.18	5e-07	1.20±0.03	4e-09
347.2592	5.7103	1.37±0.20	3e-12	0.58±0.12	9e-07	0.84±0.13	2e-11	0.79±0.17	3e-06	1.15±0.03	2e-06
347.2597	5.2972	0.99±0.20	6e-07			0.59±0.13	4e-06			1.13±0.03	2e-05
347.2598	5.6209	1.81±0.19	5e-21	0.73±0.11	2e-10	1.09±0.12	5e-19	1.08±0.17	8e-11	1.25±0.03	1e-13
349.2006	3.5705							0.78±0.17	2e-06		
349.2022	2.3032					0.52±0.13	4e-05				
349.2023	1.5047									0.88±0.03	3e-05
349.2023	1.5602	-0.91±0.19	3e-06			-0.49±0.12	7e-05			0.87±0.03	1e-05
349.2024	3.4472	0.93±0.20	2e-06					0.90±0.17	8e-08		
351.2173	2.3865			0.55±0.12	3e-06	0.56±0.12	8e-06				
351.2180	1.3937	-1.07±0.20	6e-08			-0.58±0.13	5e-06	-0.74±0.17	1e-05	0.85±0.03	1e-07
351.2184	2.8182					0.50±0.12	5e-05				
351.2185	1.2518	-0.89±0.20	5e-06			-0.53±0.12	2e-05			0.85±0.04	9e-06
351.2189	0.9743	-0.89±0.20	5e-06								
351.2192	1.9733	-1.02±0.20	2e-07			-0.49±0.12	9e-05	-0.79±0.17	2e-06	0.86±0.03	2e-07
353.2313	2.6671	0.83±0.19	1e-05	0.49±0.11	2e-05	0.60±0.12	8e-07				
353.2336	2.3927	1.36±0.20	3e-12	0.76±0.12	8e-11	0.96±0.12	1e-14			1.19±0.03	4e-09
353.2337	1.9487	1.21±0.20	3e-09	0.77±0.12	4e-10	0.91±0.13	2e-12			1.16±0.03	5e-07
355.2431	2.0658	-0.76±0.19	7e-05								
359.2230	3.2128	1.53±0.19	2e-15	0.60±0.11	2e-07	0.91±0.12	1e-13	0.93±0.17	2e-08	1.20±0.03	4e-10
361.2368	3.1142	1.39±0.20	2e-12	0.59±0.12	7e-07	0.86±0.13	1e-11	0.80±0.17	2e-06	1.15±0.03	3e-06
361.2381	3.6445	1.17±0.20	2e-09			0.55±0.13	1e-05	0.93±0.17	3e-08	1.14±0.03	5e-06
361.2383	3.4040	1.34±0.20	2e-11	0.48±0.12	7e-05	0.76±0.13	2e-09	0.87±0.17	6e-07	1.14±0.03	9e-06
361.2392	3.3454	1.32±0.19	8e-12	0.58±0.12	6e-07	0.82±0.12	2e-11	0.75±0.17	7e-06	1.15±0.03	5e-07
361.2394	3.4718	0.95±0.20	1e-06			0.52±0.13	3e-05				
361.2394	3.8141	1.90±0.19	1e-22	0.66±0.12	1e-08	1.07±0.12	5e-18	1.24±0.17	1e-13	1.25±0.03	3e-13
361.2395	3.4996	1.24±0.20	5e-10			0.52±0.13	4e-05	1.08±0.17	3e-10	1.13±0.03	2e-05
361.2398	3.7062	1.43±0.19	2e-13			0.71±0.12	1e-08	1.08±0.17	1e-10	1.16±0.03	3e-07
361.2405	4.0762	1.10±0.19	1e-08			0.55±0.12	1e-05	0.83±0.17	6e-07	1.13±0.03	2e-05
363.2545	3.8048	1.95±0.21	4e-21	0.61±0.12	7e-07	1.06±0.13	1e-15	1.34±0.18	6e-14	1.23±0.03	6e-12
367.2094	1.6897	0.82±0.19	2e-05								

M/Z	RT	Systolic BP		Diastolic BP		MAP		Pulse pressure		Hypertension	
		β±SE	p	β±SE	p	β±SE	p	β±SE	p	β±SE	p
367.2137	0.9003	-1.16±0.20	1e-08			-0.60±0.13	4e-06	-0.83±0.18	2e-06	0.84±0.04	4e-07
375.2184	3.7709			-0.56±0.11	9e-07						
377.2314	4.5140	1.67±0.19	7e-18	0.49±0.12	3e-05	0.88±0.12	1e-12	1.18±0.17	1e-12	1.23±0.03	3e-13
391.2130	1.7082	-0.81±0.19	3e-05							0.87±0.03	5e-06
403.2499	5.0782	1.91±0.21	8e-20			0.96±0.13	8e-13	1.43±0.18	3e-15	1.23±0.03	4e-11
407.2038	3.4472	1.19±0.21	8e-09			0.64±0.13	1e-06	0.83±0.18	3e-06		
495.2604	3.0248	1.08±0.20	3e-08					0.95±0.17	2e-08	1.13±0.03	2e-05
495.2606	3.0587	1.20±0.19	6e-10			0.63±0.12	4e-07	0.86±0.17	3e-07	1.15±0.03	9e-07

The relation between each eicosanoid and blood pressure variables was analyzed in separate linear regression models with age, sex, BMI, current smoking, diabetes, antihypertensive medication, and batch as covariates. LQ/MS, liquid chromatography-mass spectrometry; MAP, mean arterial pressure; BP, blood pressure; M/Z, mass-to-charge ratio; RT, liquid chromatography retention time; β, effect size; SE, standard error.

Table S2. The association between of a six-eicosanoid risk score with systolic BP and hypertension in the discovery cohort (FINRISK).

	N of individuals	N with HTN	Effect size for systolic blood pressure		Odds for hypertension	
			Unadjusted β (95% CI)	Adjusted β (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Per 1-SD			4.46 (4.04–4.88)	3.55 (3.17–3.92)	1.44 (1.38–1.51)	1.40 (1.33–1.48)
p			<0.001	<0.001	<0.001	<0.001
Quartile						
Q1	2025	698	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
Q2	2025	804	3.15 (1.95–4.35)	2.44 (1.39–3.49)	1.25 (1.10–1.42)	1.21 (1.05–1.40)
Q3	2025	926	5.81 (4.61–7.01)	4.71 (3.66–5.76)	1.60 (1.41–1.82)	1.58 (1.37–1.83)
Q4	2024	1139	11.52 (10.32–12.73)	9.04 (7.98–10.10)	2.45 (2.16–2.78)	2.26 (1.96–2.62)

We calculated eicosanoid risk score for each participant according to the formula $\beta_1 X_1 + \beta_2 X_2 + ... + \beta_n X_n$, with X_n denoting the standardized value for the nth eicosanoid abundance, and β_n denoting the regression coefficient from the regression model containing the indicated eicosanoids. Analyses are adjusted for age, sex, BMI, current smoking, diabetes and antihypertensive medication and batch. HTN, hypertension; OR, odds ratio; CI, confidence interval.

Table S3. The association between of a six-eicosanoid risk score with systolic BP and hypertension in the discovery cohort (Framingham Offspring Study).

	N of individuals	N with HTN	Effect size for systolic blood pressure		Odds for hypertension	
			Unadjusted β (95% CI)	Adjusted β (95% CI)	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Per 1-SD			2.72 (2.10–3.35)	2.22 (1.62–2.82)	1.38 (1.27–1.50)	1.32 (1.21–1.44)
p			<0.001	<0.001	<0.001	<0.001
Quartile						
Q1	715	345	1.0 (referent)	1.0 (referent)	1.0 (referent)	1.0 (referent)
Q2	715	406	3.77 (2.01–5.52)	2.77 (1.09–4.45)	1.41 (1.14–1.74)	1.27 (1.01–1.59)
Q3	715	434	4.90 (3.15–6.66)	3.67 (1.99–5.35)	1.66 (1.34–2.04)	1.45 (1.15–1.83)
Q4	714	488	8.45 (6.69–10.21)	6.81 (5.11–8.51)	2.32 (1.87–2.87)	1.99 (1.57–2.52)

We calculated eicosanoid risk score for each participant according to the formula $\beta_1 X_1 + \beta_2 X_2 + ... + \beta_n X_n$, with X_n denoting the standardized value for the nth eicosanoid abundance, and β_n denoting the regression coefficient from the regression model containing the indicated eicosanoids in FINRISK. Analyses are adjusted for age, sex, BMI, current smoking, diabetes and antihypertensive medication and batch. HTN, hypertension; OR, odds ratio; CI, confidence interval.